Home
Conference Highlights
View All Conference Highlights
Year in Review / Wrap-Ups
Wrap-Ups
Year in Review
Contact Us
Year in Review / Wrap-Ups
Year in Review
Year in Review
2023
2022
2021
LBCL 2022 Year in Review
NSCLC IO 2022 Midyear Review
AACR & ASCO 2021 – Midyear Review
Dual IO 2021 Year in Review
Year in Review
First-Line Nivolumab plus Ipilimumab Combined with 2 Cycles of Chemotherapy in Patients with Stage IV/Recurrent NSCLC: 2-Year Update of CheckMate-9LA
Dual IO 2021 - Year in Review
Nivolumab plus ipilimumab combined with 2 cycles of chemotherapy for the treatment of advanced NSCLC demonstrates durable efficacy compared with 4 cycles of chemotherapy alone in a 2-year follow-up study.
Read More ›
Year in Review
Four-Year Follow-Up Data for First-Line Nivolumab Combined with Ipilimumab in NSCLC: CheckMate-227
Dual IO 2021 - Year in Review
After more than 4 years of follow-up, patients with advanced NSCLC treated with nivolumab plus ipilimumab maintained overall survival rates.
Read More ›
Year in Review
Durvalumab Alone or in Combination with Tremelimumab and Chemotherapy versus Chemotherapy Alone as First-Line Treatment for Metastatic NSCLC: POSEIDON Study
Dual IO 2021 - Year in Review
Durvalumab plus standard-of-care chemotherapy and durvalumab with tremelimumab plus standard-of-care chemotherapy were both associated with better progression-free survival compared with standard-of-care chemotherapy alone in the treatment of metastatic NSCLC.
Read More ›
Videos
Year in Review
Benefits of Dual Immune Checkpoint Inhibitor Therapy in Metastatic NSCLC
By
Mark A. Socinski, MD
Dual IO 2021 - Year in Review
Dual immune checkpoint inhibitor therapy provides significant and durable survival benefits over chemotherapy as first-line treatment in metastatic NSCLC.
Read More ›
Videos
Year in Review
Key Abstracts from ASCO 2021 in NSCLC
By
Mark A. Socinski, MD
AACR & ASCO 2021 – Midyear Review
Dr Mark Socinski reviews a broad variety of studies, including the evolving role of
EGFR
inhibitors and immunotherapy in NSCLC, the benefits of immunotherapy plus chemotherapy, and the impact of immune-related adverse events on clinical outcomes in NSCLC.
Read More ›
Year in Review
Atezolizumab versus Best Supportive Care After Adjuvant Chemotherapy for Resected NSCLC (IMpower010)
AACR & ASCO 2021 – Midyear Review
Adjuvant atezolizumab extends disease-free survival after adjuvant chemotherapy compared with best supportive care after adjuvant chemotherapy in patients with resected stage II/IIIA non–small-cell lung cancer (NSCLC).
Read More ›
Year in Review
2021 Midyear Review: Non–Small-Cell Lung Cancer
AACR & ASCO 2021 – Midyear Review
Every year, researchers and clinicians report on exciting advancements in the diagnosis and treatment of cancer. In 2021, despite the COVID-19 pandemic, developments in the management of lung cancer continue to be important and intriguing.
Read More ›
Year in Review
Combination of Nivolumab and Chemotherapy in Nonmetastatic Resectable NSCLC (CheckMate-816)
AACR & ASCO 2021 – Midyear Review
Combining nivolumab with a limited course of chemotherapy in resectable non–small-cell lung cancer (NSCLC) enhances rates of pathologic complete response compared with chemotherapy alone.
Read More ›
Year in Review
Phase 3 Study of Tislelizumab Compared with Docetaxel in Advanced NSCLC (RATIONALE 303)
AACR & ASCO 2021 – Midyear Review
Based on results of the RATIONALE 303 trial, tislelizumab significantly prolonged median overall survival by more than 5 months in patients with advanced non–small-cell lung cancer (NSCLC) compared with docetaxel.
Read More ›
Year in Review
Acquired Resistance Mutations After Treatment of EGFR-Mutated Metastatic NSCLC with Osimertinib plus Savolitinib (TATTON)
AACR & ASCO 2021 – Midyear Review
Resistance to the combination of osimertinib plus savolitinib is predominantly mediated by acquired mutations in either
MET
,
EGFR
, or
KRAS
in patients with
EGFR
-mutated metastatic non–small-cell lung cancer (NSCLC).
Read More ›
Page 7 of 9
1
2
3
4
5
6
7
8
9
Home
Conference Highlights
View All Conference Highlights
Year in Review / Wrap-Ups
Wrap-Ups
Year in Review
Contact Us